Chemomab Therapeutics (CMMB) Net Income towards Common Stockholders (2017 - 2025)

Chemomab Therapeutics (CMMB) has 8 years of Net Income towards Common Stockholders data on file, last reported at -$16.1 million in Q4 2025.

• For the quarter ending Q4 2025, Net Income towards Common Stockholders rose 35.34% year-over-year to -$16.1 million; the trailing twelve-month figure through Dec 2025 stood at -$14.4 million (down 3.08% YoY), and the FY2025 full-year result was -$9.0 million, up 35.5% from the prior year.
• Net Income towards Common Stockholders for Q4 2025 stood at -$16.1 million, down from $1.7 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $8.7 million in Q1 2023 and bottomed at -$24.9 million in Q4 2024.
• The 5-year median for Net Income towards Common Stockholders is $3.5 million (2024), against an average of $213705.9.
• The widest annual swing landed in 2022, when Net Income towards Common Stockholders soared 372.24%; it then sank 829.5% in 2024.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$5.0 million in 2021, then soared by 263.86% to $8.3 million in 2022, then tumbled by 58.59% to $3.4 million in 2023, then tumbled by 829.5% to -$24.9 million in 2024, then jumped by 35.34% to -$16.1 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at -$16.1 million (Q4 2025), $1.7 million (Q3 2025), and -$24.9 million (Q4 2024), per Business Quant data.

Peer Comparison